Theresa Heggie was appointed to the Board in December 2018, bringing more than 30 years of experience as a business leader in the pharmaceutical, biotechnology, and rare disease industries. Ms. Heggie most recently served as Chief Operating Officer of ProQR, a company developing RNA therapies for genetic eye diseases. Prior to joining ProQR in 2021, she was Chief Executive Officer of Freeline, and before that was Senior Vice President, Head of Europe, Middle East, and Africa, and Canada for Alnylam Pharmaceuticals, and Global Chief Strategy and Marketing Officer for Bupa. Ms. Heggie also served as Senior Vice President of global commercial operations for Shire Human Genetic Therapies (HGT).
Ms. Heggie joined Shire in 2005 as part of the acquisition of TKT where she was responsible for HGT’s business in Europe, Middle East, and Africa, and, following the acquisition of Jerini in 2008, was appointed Chief Executive Officer of Jerini AG based in Berlin. Prior to joining Shire, Ms. Heggie spent more than 20 years in the pharmaceutical industry with Janssen Pharmaceuticals, Ohmeda Pharmaceutical Products Division (part of BOC), and Baxter in marketing, sales, and clinical research roles. Ms. Heggie received her B.S. from Cornell University.
What is Theresa Heggie's net worth?
The estimated net worth of Theresa Heggie is at least $499.29 thousand as of August 13th, 2025. Heggie owns 65,352 shares of BioCryst Pharmaceuticals stock worth more than $499,289 as of December 10th. This net worth approximation does not reflect any other assets that Heggie may own. Learn More about Theresa Heggie's net worth.
How do I contact Theresa Heggie?
Has Theresa Heggie been buying or selling shares of BioCryst Pharmaceuticals?
Theresa Heggie has not been actively trading shares of BioCryst Pharmaceuticals within the last three months. Most recently, Theresa Heggie sold 70,000 shares of the business's stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a transaction totalling $595,700.00. Following the completion of the sale, the director now directly owns 65,352 shares of the company's stock, valued at $556,145.52. Learn More on Theresa Heggie's trading history.
Who are BioCryst Pharmaceuticals' active insiders?
BioCryst Pharmaceuticals' insider roster includes George Abercrombie (Director), Steve Aselage (Director), Yarlagadda Babu (Insider), Alane Barnes (Insider), Anthony Doyle (CFO), Steven Galson (Director), Theresa Heggie (Director), Nancy Hutson (Director), Alan Levin (Director), Amy McKee (Director), Vincent Milano (Director), Machelle Sanders (Director), William Sheridan (Insider), Jon Stonehouse (CEO), and Helen Thackray (Chief Research & Development Officer). Learn More on BioCryst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of BioCryst Pharmaceuticals?
During the last twelve months, insiders at the biotechnology company sold shares 4 times. They sold a total of 231,680 shares worth more than $1,760,101.16. The most recent insider tranaction occured on December, 3rd when insider Alane P Barnes sold 19,770 shares worth more than $151,240.50. Insiders at BioCryst Pharmaceuticals own 5.1% of the company.
Learn More about insider trades at BioCryst Pharmaceuticals. Information on this page was last updated on 12/3/2025.
